



**UNITED STATES  
NUCLEAR REGULATORY COMMISSION**  
WASHINGTON, D.C. 20555-0001

February 16, 2012

Henry D. Royal, M.D.  
Executive Director, American Board  
of Nuclear Medicine  
4555 Forest Park Boulevard  
Suite 119  
St. Louis, Missouri 63108-2173

Dear Dr. Royal:

I am writing in response to your letter dated February 10, 2012, regarding the training and experience requirements for the medical use of Radium-223 chloride. I appreciate the American Board of Nuclear Medicine sharing their views and recommendation to license the therapeutic use of alpha emitters under Title 10 Code of Federal Regulations 35.300. NRC staff will consider this information when licensing new therapies.

Sincerely,

A handwritten signature in black ink, appearing to read "CE Einberg", is written over the typed name.

Christian E. Einberg  
Chief, Radioactive Materials  
Safety Branch  
Division of Materials Safety and  
State Agreements  
Office of Federal and State Materials  
and Environmental Management  
Programs